Noom vs Omzo
Noom and Omzo both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you are choosing between Noom and Omzo, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Noom leads our six-part score, 6.9 to 5.5.
Noom vs Omzo price
Noom and Omzo start at the same figure, $179 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide costs the same at both, $179 a month; tirzepatide is cheaper at Omzo ($279 a month vs $349 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format, Noom prices compounded injections and brand-name pens, while Omzo prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, Noom is the only one of the two with a brand-name price.
Where each one treats patients
Neither Noom nor Omzo publishes the states it serves, so enter your state at the very start of each sign-up.
Pricing
Noom
The first 3 weeks of the program with 4 weeks of medication start from $149, then $349 per month plus tax on a 12-week subscription. The program also offers generic liraglutide.
The first 3 weeks with 4 weeks of medication start from $79, then $179 per month plus tax on a 12-week subscription. Compounded tirzepatide is also offered on this plan.
Omzo
What each price covers
Both prices cover the clinician visit.
Noom's price also covers coaching, which Omzo does not claim.
Omzo's price also covers the medication itself and shipping, which Noom does not claim.
Noom is silent on the medication itself, shipping and lab work.
Omzo is silent on lab work and coaching.
That matters most for the drug: unless Noom confirms otherwise, budget for medication on top of its listed price.
Noom
Covered by the monthly price
Medication
Not stated
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
In the price
Omzo
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, Noom scores 6.9 and Omzo 5.5 out of 10.
Noom is stronger on value (5.2 vs 3.0), user experience (8.0 vs 3.0) and trust & safety (6.5 vs 4.0).
Omzo is stronger on support (7.0 vs 4.0).
Effectiveness and accessibility are within half a point.
Noom
6.9/10
Omzo
5.5/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither Noom nor Omzo has an FDA warning letter on record with us.
Features & Coverage
| Feature | Noom | Omzo |
|---|---|---|
| Starting Price | $179/mo | $179/mo |
| Features | 2 features | ✓8 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warning Letters | None | None |
About Noom
Noom is a behavioral weight loss app. It also prescribes GLP-1 medications through Noom Med.
Read our full Noom review →About Omzo
Prices appear only once the intake quiz is finished. Beyond that, Omzo declines to identify its legal entity, its pharmacy or the states it operates in. The service spans six pillars: skin, hair, sexual health, women's hormone health, daily health and weight loss, and its clinician-guided GLP-1 line covers compounded semaglutide and tirzepatide. Delivery is free and discreet, FSA/HSA money qualifies, and an independent state-licensed compounding pharmacy fills the prescriptions.
Read our full Omzo review →Pros & Cons
Noom
What we like
- Semaglutide costs $179 a month, close to the $185 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $349 a month, 72% below the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes clinician visits and coaching
- We found no FDA warning letters issued to Noom
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Omzo
What we like
- The monthly price includes the medication, clinician visits and shipping
- We found no FDA warning letters issued to Omzo
Watch-outs
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Noom wins this one, 6.9 to 5.5, above all for coaching bundled into the price rather than sold separately.
Choose Noom if…
You want coaching bundled into the price rather than sold separately and an opening price near $179 a month.
Choose Omzo if…
You want the lower starting price and an opening price near $179 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →RxSpan MD
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $249/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $249/mo
Get started →Noom vs Omzo: FAQ
Close alternatives to Noom and Omzo
- Noom vs GOAL.MD
- Noom vs Vaylen
- Noom vs DudeMeds
- Noom vs Healthicare
- Omzo vs Nurx
- Omzo vs Bodybuilding Health+
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.